Psittacine Atherosclerosis: Antemortem Diagnosis and Management

Bottom line

Psittacine atherosclerosis is usually a presumptive antemortem diagnosis assembled from signalment, episodic clinical signs, vascular imaging, and exclusion of more treatable mimics. No routine blood test or imaging result independently confirms or excludes the disease, and medical treatment remains largely supportive and anecdotal. Stabilize the dyspneic or neurologically unstable bird before pursuing a staged workup, because handling and anesthesia can be consequential in advanced cardiovascular disease.

Pathophysiology and clinical context

Avian atherosclerosis involves proliferative lipid-rich lesions of elastic and muscular arteries, with the aorta and brachiocephalic arteries prominent sites in pet birds. Plaques may narrow the lumen, disturb flow, damage endothelium, promote thrombosis, or contribute to aneurysmal change. Merck describes Amazon parrots, Quaker parrots, macaws, and African grey parrots as apparently susceptible groups; reported presentations include exercise intolerance, dyspnea, episodic weakness, seizures, tremors, paresis, and sudden death.[1]

The presentation is not disease-specific. Dyspnea may reflect lower respiratory disease, air-sac compromise, coelomic mass effect, anemia, or cardiac failure. Weakness, collapse, or seizures may arise from heavy-metal toxicosis, hypocalcemia, hypoglycemia, hepatic disease, trauma, arrhythmia, or primary neurologic disease. Atherosclerosis may be incidental, contributory, or the dominant lesion, and those possibilities cannot always be separated in a living bird.

Signalment should modify suspicion, not substitute for diagnosis. In a multicenter retrospective study based on records from five pathology centers, 7,683 psittacine birds included 525 with advanced lesions; increasing age, female sex, and the genera Psittacus, Amazona, and Nymphicus were associated with clinically relevant atherosclerosis detected at necropsy.[2] This pathology-derived cohort identifies associations among submitted birds. It is not a prevalence estimate for healthy living parrots or for every species within those genera.

A smaller retrospective case-control study compared 31 psittacine birds with histologically diagnosed atherosclerosis with 31 controls selected from necropsy records. Higher plasma cholesterol and vascular Chlamydophila psittaci antigen were associated with case status after the reported adjustments.[3] That association does not establish that infection caused the vascular lesions, nor does it make chlamydial testing a stand-alone atherosclerosis test.

Stabilization and initial workup

Triage the bird's respiratory effort, mentation, perfusion, posture, and ability to perch before restraint. A bird with open-mouth breathing, marked tail bobbing, repeated collapse, active seizures, or severe weakness should receive low-stress stabilization in an oxygen-enriched, thermoneutral environment as indicated. Defer nonessential restraint until the patient tolerates it. Record body weight and obtain a detailed timeline of collapse, exercise intolerance, falls, altered voice, coughing, abdominal distension, and neurologic episodes.

Ask about diet composition rather than labeling the diet simply as seed or pellet, opportunity for flight and exercise, reproductive activity, prior obesity or weight loss, exposure to metals and aerosols, and all medications. Review previous weights, plasma chemistry, radiographs, and anesthetic events. A normal auscultation does not rule out vascular disease, and a murmur or arrhythmia does not identify atherosclerosis as its cause.

Once stable, a minimum database may include CBC, plasma biochemistry, packed cell volume or total solids, and species-appropriate targeted testing driven by the differential list. Evaluate cholesterol and triglycerides in context with fasting status, reproductive state, body condition, hepatobiliary findings, diet, and the laboratory method. Consider ionized calcium, bile acids, heavy-metal testing, infectious testing, and other studies only when the presentation supports them.

Imaging strategy

Start with diagnostic-quality orthogonal whole-body radiographs when patient stability permits. Assess the cardiac silhouette, hepatic silhouette, pulmonary pattern, air sacs, coelomic detail, and visible great vessels. Increased vascular radiodensity, tortuosity, focal or linear mineralization, or an enlarged dense right aortic arch may increase suspicion, but technique and superimposition limit interpretation. Absence of visible mineralization cannot exclude nonmineralized or anatomically occult plaque.

Echocardiography complements vascular assessment by evaluating chamber size, wall motion, contractility, valves, flow, pericardial fluid, and secondary congestion. ECG is useful when an arrhythmia is suspected, but neither echo nor ECG directly surveys all arterial plaque. Interpret cardiac dysfunction as a phenotype requiring its own differential diagnosis rather than automatic proof of atherosclerosis.

The avian vascular-imaging literature describes radiography, fluoroscopy, endoscopy, CT, angiography, and transcoelomic or transesophageal ultrasonography; the 2010 review emphasizes that further research is needed to define their clinical performance.[4] CT can show mineralization and associated cardiopulmonary changes, while contrast CT angiography can better depict luminal narrowing and vascular anatomy. Patient size, motion, contrast timing, spatial resolution, anesthesia risk, and local expertise affect diagnostic yield. A negative CT therefore lowers confidence only to the extent that the protocol could visualize the relevant vessels and lesion type.

Use endoscopy opportunistically only when its expected benefit justifies invasiveness; it can visualize accessible great vessels but cannot map the entire arterial tree. Definitive lesion classification remains histopathologic, usually postmortem. If necropsy is performed, request systematic evaluation of the aorta, brachiocephalic arteries, coronary arteries, and other clinically relevant vessels rather than relying on a gross impression alone.

Interpreting lipids without overcalling disease

Total cholesterol is neither a rule-in nor a rule-out test. Hyperlipidemia may accompany reproductive activity, diet-related metabolic disease, hepatic disease, or other physiologic and pathologic states, while affected birds may lack a striking total-cholesterol increase. Method-specific and genus-specific interpretation matters.

A 2025 retrospective cohort analyzed 1,199 blood samples from 692 parrots across 14 genera and reported genus-related lipoprotein differences. LDL cholesterol was associated with moderate-to-severe atherosclerosis, but the authors explicitly concluded that LDL and non-HDL cholesterol are not sole indicators of disease and should be interpreted with other risk variables.[5] The birds came from a specialized European parrot practice, repeated observations occurred in the source dataset, and atherosclerosis classification depended on available endoscopic or necropsy information. Use these results for risk stratification, not as a validated universal diagnostic cutoff.

Trend results only when preanalytic conditions and the assay are comparable. A change in cholesterol may help monitor metabolic management, but it does not demonstrate plaque regression. Conversely, a normal lipid result should not end the workup of a high-risk bird with compatible episodic signs or convincing vascular imaging.

Management and monitoring

Separate acute cardiovascular stabilization from long-term atherosclerosis management. Treat documented heart failure, arrhythmia, effusion, thrombosis, or another concurrent disorder according to the patient's hemodynamic phenotype and current avian pharmacology resources. Avoid selecting a cardiac drug solely because atherosclerosis is suspected: outflow obstruction, dehydration, renal compromise, and uncertain ventricular function can materially change the risk-benefit assessment.

For a stable overweight or sedentary bird, build a gradual, species-appropriate nutrition and activity plan. Correct an imbalanced high-fat diet without abrupt food withdrawal or inducing caloric deficit, and increase controlled activity only within the bird's cardiopulmonary tolerance. Coordinate reproductive management and address hepatic lipidosis or other dyslipidemic conditions when present. Merck characterizes medical treatment of avian atherosclerosis as anecdotal, reports inconsistent efficacy of advocated cholesterol-lowering approaches, and notes that evidence supporting statins in birds is sparse.[1] Do not promise plaque reversal or import a human lipid target into parrot practice.

Establish measurable monitoring endpoints: body weight and condition, resting respiratory effort, frequency and context of collapse or neurologic episodes, exercise tolerance, quality of life, relevant chemistry trends, and repeat imaging findings when a change would alter management. Teach the caregiver to record videos and event timing while avoiding forced exertion. Reassess urgently for increasing dyspnea, more frequent syncope, sustained neurologic deficits, abdominal distension, or inability to perch.

An emerging option should not be mistaken for routine availability. A 2024 proof-of-concept study scanned 10 adult Hispaniolan and 8 adult orange-winged Amazon parrots with micro-PET and micro-CT. Micro-PET detected more lesions and had greater interobserver agreement, but histopathologic comparison involved only 5 Amazon parrots.[6] These results support further investigation of molecular imaging; they do not validate a universal screening pathway, performance estimate, or treatment endpoint for all psittacine species.

Frequently Asked Questions

Can a high cholesterol result diagnose atherosclerosis in a parrot? No. Lipids contribute to risk assessment, but values vary by genus, diet, reproductive state, assay, and concurrent disease. The Janeczek et al. parrot cohort concluded that LDL and non-HDL cholesterol are not sole indicators of atherosclerosis.[5]

Does a normal radiograph rule out psittacine atherosclerosis? No. Radiographs may reveal mineralized or tortuous great vessels and secondary cardiopulmonary changes, but nonmineralized, small, or superimposed lesions can remain occult. Escalate imaging only if patient stability and the expected decision value justify it.

Should CT or CT angiography be the next test? Use it when vascular anatomy or luminal narrowing would change management and the bird can safely undergo the required protocol. CT is not a binary exclusion test; spatial resolution, motion, contrast timing, lesion mineralization, and operator experience all affect yield.

Is there a proven drug that reverses plaque in parrots? No consistent plaque-reversing medical protocol has been established. Merck describes treatment as anecdotal and notes little supporting information for statin use in birds.[1] Direct therapy toward documented complications and modifiable husbandry or metabolic factors.

How should pathology prevalence figures affect a living patient's workup? Use them to weight signalment, not to assign an individual probability. The Beaufrère et al. multicenter dataset comprised 7,683 pathology records, including 525 birds with advanced lesions, so its associations reflect submitted birds evaluated at necropsy.[2]

Does a positive Chlamydia test establish the cause of atherosclerosis? No. Pilny et al. found an association between vascular antigen staining and atherosclerosis in a retrospective necropsy case-control study of 31 cases and 31 controls.[3] Association in that selected population does not prove causation or make routine infection testing diagnostic for plaque.

Is sodium-fluoride PET ready for routine screening? Not yet. The Megan et al. proof-of-concept study involved 10 Hispaniolan and 8 orange-winged Amazon parrots, with histopathologic comparison in 5 birds.[6] It is promising emerging imaging evidence, not a validated general screening standard for all parrots.